Metformin in frozen embryo replacement cycles in women with PCOS
Research type
Research Study
Full title
The effect of metformin co-treatment in hormone-replacement frozen embryo replacement cycles in women with polycystic ovary syndrome.
IRAS ID
24344
Contact name
Adam Balen
Contact email
Sponsor organisation
THE LEEDS TEACHING HOSPITALS NHS TRUST
Eudract number
2009-017245-64
ISRCTN Number
N/A
Clinicaltrials.gov Identifier
N/A
Research summary
A large proportion of patients seeking fertility treatments have a condition called polycystic ovary syndrome (PCOS). Women with PCOS suffer from impaired fertility potential due to abnormalities of the ovarian function and womb lining. In a frozen embryo replacement cycle thawed-frozen embryos are placed into the womb, preceding this the woman recieves hormones to prepare the womb for the embryo. Women with PCOS have been observed to have abnormal womb lining development. The drug metformin has been observed to improve features of PCOS and studies have observed favourable changes to the womb lining making the womb more receptive to the embryo. It is hypothesised that metformin would, therefore, enhance a womans chance of pregnancy following a frozen embryo replacement cycle. In this study we compare metformin to placebo given as cotreatment during frozen embryo replacement to determine if pregnancy rates and womb receptivity to the embryo are enhanced.
REC name
Yorkshire & The Humber - Leeds West Research Ethics Committee
REC reference
09/H1307/108
Date of REC Opinion
19 Jan 2010
REC opinion
Further Information Favourable Opinion